Format

Send to

Choose Destination
Neurourol Urodyn. 2019 Nov 6. doi: 10.1002/nau.24207. [Epub ahead of print]

Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICI-RS 2019?

Author information

1
Department of Urology, Guy's Hospital, London, UK.
2
2nd Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
4
Department of Urology, Uniklinik Aachen RWTH, Aachen, Germany.
5
Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands.
6
Department of Urogynaecology, King's College Hospital, London, UK.
7
School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.

Abstract

AIMS:

Botulinum toxin A (BTX-A) is a well-established treatment for refractory idiopathic overactive bladder (OAB). It has also been used with short-term success in treating idiopathic urinary retention. However, efficacy and complication rates are variable and predicting those likely to benefit most from treatment would enable personalization of therapy and optimization of outcomes. At the International Consultation on Incontinence-Research Society (ICI-RS) meeting in 2019 a Think Tank addressed the question of how we can improve the way we phenotype patients undergoing BTX-A treatment.

METHODS:

The Think Tank conducted a literature review and expert consensus meeting focussing on how advances in basic science research of the mechanism of action of BTX-A, as well as assessment of psychological comorbidity, can be translated into clinical practice to improve patient selection for therapy.

RESULTS:

Idiopathic OAB and idiopathic urinary retention are heterogenous conditions encompassing several phenotypes with multiple potential pathophysiological mechanisms. Animal models have demonstrated a central nervous system mechanism of action of intravesically injected BTX-A and this has been confirmed in human functional MRI studies, but whether this tool can be used to predict outcome from treatment remains to be determined. Phenotyping based on psychological comorbidity using validated screening tools should be studied as a way to potentially optimize patient selection for therapy.

CONCLUSIONS:

Advances in basic science research into the mechanism of action of BTX-A have improved our understanding of the pathophysiology of OAB and may lead to novel ways to phenotype patients. Psychological assessment is another way in which phenotyping may be improved. Areas for further research are proposed.

KEYWORDS:

Botulinum toxin; overactive bladder; phenotype; urinary retention

PMID:
31692092
DOI:
10.1002/nau.24207

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center